Evidence map›Paper›PMID 42366058›Full record

ArticleJournal of clinical and experimental hematopathology : JCEH2026

Independent PML::RARA-positive acute promyelocytic leukemia arising during BCR::ABL1-positive chronic myeloid leukemia.

Takanori Yoshioka, Akira Kondo, Masayuki Matsuda, Yasuhisa Sando, Makoto Nakamura, Nobuharu Fujii, Kazutaka Sunami

Abstract readCase Reports
In one paragraph

Article in Journal of clinical and experimental hematopathology : JCEH, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Takanori YoshiokaDepartment of Hematology, National Hospital Organization (NHO) Okayama Medical Center, Okayama, Japan.
Akira KondoDepartment of Hematology, National Hospital Organization (NHO) Okayama Medical Center, Okayama, Japan.
Masayuki MatsudaDepartment of Hematology, National Hospital Organization (NHO) Okayama Medical Center, Okayama, Japan.
Yasuhisa SandoDepartment of Hematology, National Hospital Organization (NHO) Okayama Medical Center, Okayama, Japan.
Makoto NakamuraDepartment of Hematology, National Hospital Organization (NHO) Okayama Medical Center, Okayama, Japan.
Nobuharu FujiiDepartment of Hematology, Okayama University Hospital, Okayama, Japan.
Kazutaka SunamiDepartment of Hematology, National Hospital Organization (NHO) Okayama Medical Center, Okayama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute promyelocytic leukemia (APL) arising during the clinical course of BCR::ABL1-positive chronic myeloid leukemia (CML) is rare and may represent either promyelocytic blast phase or the emergence of an independent Philadelphia chromosome-negative clone. We report an octogenarian man with chronic-phase CML who was intolerant to multiple tyrosine kinase inhibitors and underwent temporary discontinuation of asciminib. During molecular relapse, bone marrow examination revealed 88% abnormal promyelocytes with Auer rods and markedly elevated PML::RARA transcripts, whereas BCR::ABL1 transcript levels were more than 3 logs lower than at CML diagnosis. Conventional cytogenetics demonstrated t(15;17) without t(9;22) as the dominant clone, supporting de novo APL arising independently of the residual CML clone. All-trans retinoic acid plus arsenic trioxide achieved molecular remission of PML::RARA and was followed by an initial marked reduction in BCR::ABL1 transcript levels, which subsequently remained detectable at low levels during continued follow-up. This case highlights the importance of integrated cytogenetic and molecular evaluation to distinguish blast phase from independent leukemogenesis in patients with CML who develop cytopenias.

Indexed as

Fusion Proteins, bcr-ablLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, Promyelocytic, AcuteOncogene Proteins, FusionRetinoic Acid Receptor alphaAged, 80 and overArsenicalsArsenic TrioxideHumansMaleOxidesPromyelocytic Leukemia ProteinArsenicalsArsenic TrioxideFusion Proteins, bcr-ablOncogene Proteins, FusionOxidesPML protein, humanPromyelocytic Leukemia Proteinpromyelocytic leukemia-retinoic acid receptor alpha fusion oncoproteinRARA protein, humanRetinoic Acid Receptor alphaacute promyelocytic leukemiaBCR::ABL1 fusionchronic myeloid leukemiaclonal evolutionPML::RARA fusion

Identifiers

PMID42366058
PMCPMC13472210

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.